LICENSE AGREEMENTLicense Agreement • November 9th, 2021 • Epizyme, Inc. • Pharmaceutical preparations • New York
THIS LICENSE AGREEMENT (this “Agreement”) is made and entered into as of August 7, 2021 (“Effective Date”) between Epizyme, Inc., a corporation organized and existing under the laws of the State of Delaware, with a principal place of business at 400 Technology Square, Cambridge, Massachusetts 02139 U.S. (“Epizyme”), and Hutchison China MediTech Investment Limited, a company organized and existing under the laws of the British Virgin Islands, with company number 2031179 and its registered office being Vistra Corporate Services Centre, Wickhams Cay II, Road Town, Tortola, VG1110, British Virgin Islands (“Hutchmed”). Epizyme and Hutchmed may be referred to herein individually as a “Party” and collectively as the “Parties.”
EPIZYME, INC. RESTRICTED STOCK UNIT AWARD AGREEMENT (the “Agreement”) Inducement Grant Pursuant to Nasdaq Stock Market Rule 5635(c)(4)Restricted Stock Unit Award Agreement • November 9th, 2021 • Epizyme, Inc. • Pharmaceutical preparations • Delaware
Epizyme, Inc. (the “Company”) has selected you to receive an award of restricted stock units (“RSUs”). The terms and conditions attached hereto are a part hereof.
CONSULTING AGREEMENTConsulting Agreement • November 9th, 2021 • Epizyme, Inc. • Pharmaceutical preparations • Massachusetts
THIS CONSULTING AGREEMENT (the “Agreement”) is entered into as of August 4, 2021 by and between Epizyme, Inc. (the “Company”), and Robert B. Bazemore (“Mr. Bazemore” or “you”) (together, the “Parties”).
